Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.
Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure.
Russell-Jones
David
D
Department of Diabetes and Endocrinology, Royal Surrey County Hospital, Egerton Road, Guildford GU2 7XX, UK. drj@royalsurrey.nhs.uk
D000595:Amino Acid Sequence; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000069450:Liraglutide; D008969:Molecular Sequence Data
D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1